Copyright
©The Author(s) 2024.
World J Clin Cases. Jul 26, 2024; 12(21): 4703-4716
Published online Jul 26, 2024. doi: 10.12998/wjcc.v12.i21.4703
Published online Jul 26, 2024. doi: 10.12998/wjcc.v12.i21.4703
Table 2 The results of meta-analysis and trial sequential analysis for safety endpoints
| Outcome | Experimental | Control | I2 | RR (95%CI) | P value | TSA |
| Total adverse events | 21/226 | 19/224 | 0 | 1.10 (0.61-1.97) | 0.75 | No |
| Gastrointestinal adverse events | 11/168 | 10/166 | 0 | 1.08 (0.50-2.36) | 0.84 | No |
| Abdominal distension | 3/73 | 3/72 | 0 | 0.99 (0.23-4.22) | 0.99 | No |
| Erythra | 3/130 | 3/128 | 0 | 0.98 (0.27-3.57) | 0.98 | No |
| Relapse | 12/116 | 29/115 | 50 | 0.41 (0.22-0.76) | 0.005 | Yes |
- Citation: Yang XY, Yu YF, Tong KK, Hu G, Yu R, Su LJ. Efficacy and safety of Xileisan combined with mesalazine for ulcerative colitis: A meta-analysis and trial sequential analysis. World J Clin Cases 2024; 12(21): 4703-4716
- URL: https://www.wjgnet.com/2307-8960/full/v12/i21/4703.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v12.i21.4703